Drug data last refreshed 16h ago · AI intelligence enriched 1mo ago
PENTOTHAL is a rectal suspension small-molecule product approved in 1959 by Abbott, representing a legacy anesthetic or sedative agent. The exact mechanism of action and clinical indications are not specified in available data, but the rectal route suggests pediatric or difficult-access patient populations. This is an NDA-approved product approaching loss of exclusivity.
Product is in late-stage lifecycle with minimal current commercial activity; team size and growth opportunities are limited.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
PENTOTHAL presents a career opportunity focused on portfolio management, generic transition planning, and niche market maintenance rather than growth or innovation. Working on this product involves strategic decision-making around discontinuation, cost optimization, or supply chain efficiency for a legacy small-molecule anesthetic.
Worked on PENTOTHAL at Abbott? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.